(Q53295993)

13 May 2018

title

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study (English)

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

1 August 2024

1 reference

E. J. Macaskill

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

J. M S. Bartlett

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

V. S. Sabine

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

D. Faratian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

L. Renshaw

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

S. White

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

F. M. Campbell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

O. Young

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

L. Williams

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

J. S. Thomas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

M. D. Barber

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

J. M. Dixon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

1 August 2024

language of work or name

English

0 references

publication date

13 October 2010

1 reference

13 May 2018

full work available at URL

https://hal.archives-ouvertes.fr/hal-00615396/file/PEER_stage2_10.1007%252Fs10549-010-0967-z.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20941539

http://link.springer.com/content/pdf/10.1007/s10549-010-0967-z.pdf

1 August 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

http://link.springer.com/article/10.1007/s10549-010-0967-z/fulltext.html

1 August 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

http://link.springer.com/content/pdf/10.1007/s10549-010-0967-z

1 August 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

Breast Cancer Research and Treatment

1 August 2024

published in

1 reference

13 May 2018

volume

128

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

725-734

1 reference

13 May 2018

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Observer variation in immunohistochemical analysis of protein expression, time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

mTOR phosphorylated at S2448 binds to raptor and rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0967-Z

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

21 January 2018

22

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

Efficiently estimated histologic cell counts

1 August 2024

27

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

The Nottingham prognostic index in primary breast cancer

1 August 2024

32

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

MIB-1 assessments in breast cancers

1 August 2024

48

1 reference

https://api.crossref.org/works/10.1007/S10549-010-0967-Z

1 August 2024

Identifiers

1 reference

13 May 2018

1 reference

13 May 2018